Bayer: FDA Priority Review for Nexavar Treatment of Thyroid Cancer

German chemical and pharmaceuticals group Bayer AG said Tuesday the U.S. Food & Drug Administration has granted a priority review of nexavar for the treatment of differentiated thyroid cancer.

MAIN FACTS:

-Bayer collaborates with Onyx Pharmaceuticals (ONXX) in the U.S. on its nexavar drug, also known as sorafenib.

-The FDA grants priority reviews to medicines with the potential to significantly improve serious conditions.

-The FDA aims to complete the review within six months, rather than the standard 10 months, Bayer said.

-The decision was based on Phase III trial data showing the drug significantly extended progression-free survival.

-Thyroid cancer is the sixth most common cancer in women, and 35,000 patients in the world succumb to the disease annually.

-The drug is an oral anti-cancer therapy for liver cancer and advanced kidney cancer.

-"Nexavar is also being evaluated by Bayer and Onyx, international study groups, government agencies and individual investigators in a range of other cancers," Bayer said.

 
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500 
 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires